Combination of selenium-containing compounds with cytostatics

Patent 6656509 Issued on December 2, 2003. Estimated Expiration Date:

February 2, 2021. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one
Patent #: 5385726
Issued on: 01/31/1995
Inventor: Baldew, et al.

Method for the preparation of free radical pharmaceuticals using selenium conjugates Patent #: 5783454
Issued on: 07/21/1998
Inventor: Spallholz, et al.

Inventors

Assignee

Biosyn Arzneimittel GmbH

Application

No. 09/701326 filed on 02/02/2001

US Classes:

424/617, Heavy metal or compound thereof424/649, Gold or platinum514/283, Ring nitrogen in the pentacyclo ring system is shared by five-membered cyclo and six-membered cyclo (e.g., vincamine, etc.)514/449, Oxygen containing hetero ring514/492Heavy metal containing DOAI

Examiners

Primary: Goldberg, Jerome D.

Attorney, Agent or Firm

Needle & Rosenberg, P.C.

International Classes

A61K 31/505 (20060101)
A61K 33/04 (20060101)
A61K 31/40 (20060101)

Foreign Application Priority Data

1998-06-09 DE

Abstract

The present invention relates to the use of selenium and/or a derivative thereof in combination with one or more cytostatics.It is the object of the present invention to provide a possibility of enhancing the effect of antitumor drugs, and to provide said drugs in a suitable form of administration.Said object is achieved by using selenium and/or at least one selenium compound for enhancing the effect of one or more cytostatics. This combination results in a synergistic, i.e. superadditive, enhancement of the effect. Furthermore, the present invention provides a kit containing selenium and/or at least one selenium compound and one or more cytostatics as a combination preparation for cytostatic therapy. The present invention can be used efficiently against various types of tumor cells, but especially against large-cell and small-cell bronchial carcinomas, adenocarcinomas, pancreatic carcinomas, prostatic carcinomas and hypemephromas.

Other References

Choie et al., Toxicology and Applied Pharmacology, (1981) 60/2 (354-359) Abstract Only.
Koepf-Maier et al., J of Cancer Research and Clinical Oncology, (1981) 102/1 (21-30) Abstract Only.
Berry et al., J Submicrosc Cytol Pathol, (1988) 20 (1), 59-66 Abstract Only.
Doroshow et al., Pharmacology and Therapeutics, 47 (3), 359-370 (1990)
Gustafson et al., Cancer Chemotherapy and Pharmacology, 28 (3), 228-230 (1991)
Kiremidjian-Schumacher et al., Biological Trace Element Research, 33 (1), 23-35 (1992)
Kramer, Deutsche Zeitschrift fur Onkologie, 26 (3), 76-83 (1994)
Saltiel et al., The Western Journal of Medicine, 139 (3), 332-341 (1983)
Strama et al., Zeitschrift fur Onkologie, 29 (1), 24-25 (1997)